Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Crinetics Pharmaceuticals, Inc. (CRNX) had Cost of Goods Sold of $0.15M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$25.12M |
|
$-120.86M |
|
|
Cost of Goods Sold |
$0.15M |
$24.96M |
|
$157.58M |
|
$-132.46M |
|
$11.60M |
|
$-120.86M |
|
$-120.86M |
|
$-120.86M |
|
$-120.86M |
|
$-120.86M |
|
$-120.86M |
|
$-132.46M |
|
$-133.41M |
|
105.56M |
|
105.56M |
|
$-1.14 |
|
$-1.14 |
|
| Balance Sheet Financials | |
$1.24B |
|
$13.07M |
|
$77.52M |
|
$1.32B |
|
$79.92M |
|
-- |
|
$50.01M |
|
$129.92M |
|
$1.19B |
|
$1.19B |
|
$1.19B |
|
105.81M |
|
| Cash Flow Statement Financials | |
$-218.90M |
|
$-226.07M |
|
$398.80M |
|
$102.34M |
|
$56.30M |
|
$-46.04M |
|
$54.56M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.57 |
|
-- |
|
-- |
|
-- |
|
-- |
|
99.39% |
|
-527.35% |
|
-527.35% |
|
-- |
|
-481.15% |
|
-481.15% |
|
$-220.24M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
0.04 |
|
2.10 |
|
42.84 |
|
-10.14% |
|
-10.14% |
|
-9.14% |
|
-10.14% |
|
$11.27 |
|
$-2.09 |
|
$-2.07 |
|